导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.80% | 2241/4773 |
| 近一周 | -0.23% | 959/5491 |
| 近一月 | -4.97% | 3303/5408 |
| 近一季 | -8.28% | 3895/5202 |
| 近半年 | -5.18% | 2664/4919 |
| 近一年 | 5.11% | 1744/4356 |
| 近两年 | 68.10% | 976/2950 |
| 近三年 | 35.82% | 809/2241 |
| 成立以来 | 62.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.57% 1856/4961 |
20.29% 1238/5312 |
- - |
- - |
| 2025 | 30.86% 1281/4813 |
1.27% 1662/3635 |
0.69% 2588/4076 |
28.14% 1281/4524 |
0.15% 2179/4813 |
| 2024 | 12.00% 1282/3463 |
-1.11% 1180/2808 |
-4.04% 1460/3014 |
18.15% 1050/3129 |
-0.10% 1319/3463 |
| 2023 | -11.87% 1431/2656 |
5.56% 770/2280 |
-4.27% 1113/2385 |
-7.46% 1578/2515 |
-5.76% 1491/2655 |
| 2022 | -24.66% 1241/2207 |
-18.04% 1293/1919 |
7.00% 550/2016 |
-15.44% 1291/2113 |
1.59% 1211/2208 |
| 2021 | 6.33% 518/1822 |
-4.55% 873/1255 |
12.69% 319/1330 |
-4.09% 680/1466 |
3.07% 480/1822 |
| 2020 | 43.52% 242/1250 |
-3.88% 327/1028 |
20.62% 265/1067 |
9.74% 629/1164 |
12.79% 435/1184 |
| 2019 | 46.35% 138/1092 |
35.49% 90/739 |
-5.62% 473/788 |
3.68% 239/850 |
10.39% 140/918 |
| 2018 | -32.20% 523/834 |
- - |
-12.30% 382/631 |
-9.57% 522/660 |
-12.98% 501/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 融通深证成份指数C VS. 长安沪深300非周期A(740101) |